Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Mirza on Efficacy of Niraparib/Bevacizumab Combo in Recurrent Ovarian Cancer

September 4th 2019

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses results from the phase II NSGO-AVANOVA2/ENGOT-OV24 trial comparing niraparib with niraparib plus bevacizumab in patients with recurrent platinum-sensitive ovarian cancer.

The New Ovarian Cancer Landscape: Many Questions, Much Hope

September 3rd 2019

In the past 5 years, the FDA has awarded 4 drugs 9 new indications for the treatment of advanced ovarian cancers. Although these approvals represent a welcome expansion of the therapeutic toolkit for this challenging malignancy, the arrival of new options has outpaced efforts to discover the best use for each medication.

Projecting the Impact of Immunotherapy in Advanced Ovarian Cancer

August 30th 2019

Rebecca C. Arend, MD, discusses several ongoing trials exploring the use of immunotherapy in patients with advanced ovarian cancer.

Navigating Among Maintenance Options in Advanced Ovarian Cancer

August 30th 2019

Camille C. Gunderson, MD, discusses the various maintenance options available in advanced ovarian cancer, as well as what factors should be considered for selecting each approach.

PARP Inhibition: A Necessity of Treatment in Recurrent Ovarian Cancer

August 29th 2019

Debra Richardson, MD, FACOG, FACS, discusses the current indications for PARP inhibitors in the recurrent setting and ongoing work being done to broaden their utility in the field.

Neoadjuvant Chemo Safer Alternative for Certain Patients With Ovarian Cancer

August 29th 2019

Linda R. Duska, MD, discusses the ongoing debate between upfront surgery and neoadjuvant chemotherapy in ovarian cancer and the data that support both options.

Strategies Emerging for PARP Inhibitor Resistance in Ovarian Cancer

August 28th 2019

Kathleen Moore, MD, combs through the various investigational strategies exploring management of resistance to PARP inhibitors in ovarian cancer.

Hope Is Not Lost on Hunt for Effective Ovarian Cancer Screening Test

August 28th 2019

Laura L. Holman, MD, discusses ongoing efforts in ovarian cancer screening and what may lie ahead for generations to come.

Dr. Duska on Neoadjuvant Chemo Vs Upfront Surgery in Ovarian Cancer

August 28th 2019

Linda R. Duska, MD, discusses neoadjuvant chemotherapy versus upfront surgical debulking in patients with advanced ovarian cancer.

Prolonging PFS With PARP Inhibitors in Platinum-Sensitive Ovarian Cancer

August 22nd 2019

Alexander Olawaiye, MD, discusses the trials that led to the expanded approvals of PARP inhibitors as maintenance therapy in women with platinum-sensitive ovarian cancer.

Frontline Data for Newly Diagnosed Ovarian Cancer Leave Much to Be Discerned

August 22nd 2019

Jessica L. Berger, MD, evaluates the treatment approaches available for patients with newly diagnosed advanced ovarian cancer.

Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian Cancer

August 22nd 2019

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, poses unanswered questions pertaining to the use and reuse of PARP inhibitors in ovarian cancer treatment.

Ovarian Cancer Researchers Continue to Push the Envelope

August 21st 2019

At the 2019 OncLive® State of the Science Summit™ on Ovarian Cancer, we asked experts from the University of Pittsburgh Medical Center about the intriguing research being conducted at their institution.

Recurrent Ovarian Cancer Paradigm Continues to Evolve

August 21st 2019

Madeleine B. Courtney Brooks, MD, MPH, sheds light on the current treatment paradigm of recurrent ovarian cancer.

Immunotherapy Combo Strategies Are Major Research Focus in Ovarian Cancer

August 21st 2019

Brian Orr, MD, discusses the challenges with immunotherapy in ovarian cancer treatment while pointing to early promising data with combination regimens.

Questions Remain Across Treatment Modalities in Ovarian Cancer

August 20th 2019

John Comerci, Jr, MD, provides an overview of advances made in ovarian cancer and remaining challenges to address with future research.

PARP Inhibition Improves PFS as Frontline Maintenance in Ovarian Cancer, OS Data Awaited

August 20th 2019

Lan G. Coffman, MD, PhD, discusses pivotal trials evaluating frontline maintenance therapy in advanced ovarian cancer and unanswered questions that still need to be addressed with future research.

PARP Inhibition Continues to Make Waves in Ovarian Cancer

August 19th 2019

Terry L. Evans, MD, discusses the use of PARP inhibitors in ovarian cancer and how they are poised to optimally fit in the treatment paradigm.

Olaparib Plus Bevacizumab Improves PFS as Frontline Maintenance in Ovarian Cancer

August 14th 2019

Combining olaparib with standard bevacizumab significantly improved progression-free survival compared with bevacizumab alone as frontline maintenance therapy in women with advanced ovarian cancer, regardless of BRCA status, according to topline results from the phase III PAOLA-1 trial.

Expert Explains Intricacies of Molecular Testing in Ovarian Cancer

August 13th 2019

Sarah E. Taylor, MD, discusses the role of somatic and germline testing for patients with ovarian cancer and their family members to create more personalized treatment and prevent disease.